NCT00000818View on ClinicalTrials.gov

Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Conditions

HIV Infections

Interventions

DRUG

Zidovudine

Trial Locations (9)

32751

Goodgame Med Group, Maitland

33316

North Broward Hosp District, Fort Lauderdale

60612

Univ of Illinois, Chicago

75235

Univ of Texas Southwestern Med Ctr of Dallas, Dallas

77030

Baylor College of Medicine / Houston Veterans Adm Med Ctr, Houston

90048

Cedars Sinai Med Ctr, Los Angeles

94063

AIDS Community Research Consortium, Redwood City

94115

Mount Zion Med Ctr / UCSF, San Francisco

94304

Palo Alto Veterans Affairs Health Care System, Palo Alto

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000818 - Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3. | Biotech Hunter | Biotech Hunter